Pharsight

Fetzima generic

Fetzima is an antidepressant drug owned by Allergan. It contains levomilnacipran hydrochloride as its active ingredient, which aids in the treatment of major depressive disorder (MDD). The drug was first authorized for market use on 25 July, 2013 and is available in capsule, extended release;oral dosage forms.

When will Fetzima generic be available?

The generics of Fetzima are not yet available. However, it's expected that they could be released after 23 May, 2032, which is the expiry date of the last patent held by Fetzima. This would potentially allow for wider availability and potentially lower prices for the medication.

Fetzima uses

Fetzima is used predominantly for the treatment of major depressive disorder (MDD). Its active ingredient, levomilnacipran hydrochloride, works by regulating the balance of certain natural substances in the brain, thus helping to improve mood, sleep, appetite, and energy levels.

Fetzima patent expiration

Fetzima has a total of 3 drug patents, none of which have expired. The latest patent to expire will be US8865937, titled 'Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide', on 23 May, 2032. Following the expiry of this patent, generics of Fetzima may become available. Below are the details of the patent:

Fetzima dosage

Want to ask something?